Loading…
Solid Biosciences Inc. is projected to rise to $15.27 by 2027, a +47% move from its current price of $10.42. SLDB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $10.02 | $10.42 | $10.83 | +0.02% |
| Jul 15 | $9.87 | $10.42 | $11.01 | +0.03% |
| Jul 16 | $9.75 | $10.42 | $11.15 | +0.05% |
| Jul 17 | $9.65 | $10.43 | $11.27 | +0.06% |
| Jul 18 | $9.56 | $10.43 | $11.38 | +0.08% |
| Jul 19 | $9.48 | $10.43 | $11.47 | +0.09% |
| Jul 20 | $9.41 | $10.43 | $11.56 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.41 | $10.43 | $11.56 | +0.11% |
| Week 2 | $9.03 | $10.44 | $12.08 | +0.21% |
| Week 3 | $8.75 | $10.45 | $12.49 | +0.32% |
| Week 4 | $8.52 | $10.46 | $12.86 | +0.42% |
| Week 5 | $8.32 | $10.48 | $13.19 | +0.53% |
| Week 6 | $8.15 | $10.49 | $13.49 | +0.64% |
| Week 7 | $8.00 | $10.50 | $13.78 | +0.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Solid Biosciences Inc. is a healthcare company that develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
It also develops SGT-212 for Friedreich’s ataxia in phase 1b clinical trial, along with SGT-501, SGT-601, SGT-401 and SGT-701 across other stages of development. The organization works on platform technologies such as capsid libraries, genetic regulators (promoters, UTRs, introns), immunomodulation technologies, manufacturing purity, and dual gene expression for packaging multiple transgenes into one capsid. It maintains collaboration and license agreements with Ultragenyx Pharmaceutical Inc.
and with the University of Washington, the University of Missouri, the University of Florida, and ICS Maugeri S.p.A. Solid Biosciences was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
SLDB is a healthcare company focused on therapies for neuromuscular and cardiac diseases. The stock’s current price is $10.84 with a market capitalization of $1.07B, and it is ranked 2452 by market position. The overall price outlook shows upside over the long run, with higher average prices projected later in the forecast horizon and rising ROI across multiple years.
A major floor 56.0% below — a decisive break under it would weaken the trend.
The nearest floor, 38.5% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 35.0% above — clearing it would confirm fresh momentum.
Key SLDB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLDB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.96 | Sell | $10.73 | Sell |
| MA 10 | $10.46 | Sell | $10.35 | Buy |
| MA 20 | $9.21 | Buy | $9.53 | Buy |
| MA 50 | $7.87 | Buy | $8.41 | Buy |
| MA 100 | $7.55 | Buy | $7.69 | Buy |
| MA 200 | $6.60 | Buy | $6.95 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.95 | Neutral |
| Stoch RSI (14) | 8.25 | Buy |
| CCI (20) | 64.48 | Neutral |
| Williams %R (14) | -25.61 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 18.54 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 74.39 | Neutral |
| TRIX (15) | 1.56 | Buy |
| Awesome (5,34) | 2.73 | Buy |
| Ultimate (7,14,28) | 64.35 | Neutral |
| Momentum (10) | 1.56 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 11.14 | Sell |
| ADX (14) | 32.92 | Buy |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is bullish, with RSI14 at 80 indicating strong momentum. The stock’s 50-day simple moving average is $7.56 and the 200-day simple moving average is $6.46, reflecting an uptrend relative to longer-term averages. Near-term support is at $6.41 and resistance at $10.84, with a 30-day price range from $8.22 to $14.29.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.16 | $10.42 | $13.77 | 0% | Neutral | |
| $11.68 | $15.27 | $21.38 | +47% | Bullish | |
| $15.47 | $21.08 | $31.03 | +102% | Bullish | |
| $17.43 | $24.60 | $37.62 | +136% | Bullish | |
| $17.59 | $25.62 | $40.45 | +146% | Bullish | |
| $19.64 | $29.43 | $47.79 | +182% | Bullish | |
| $21.76 | $33.51 | $55.76 | +222% | Bullish | |
| $25.80 | $40.76 | $69.37 | +291% | Bullish | |
| $33.71 | $54.58 | $94.79 | +424% | Bullish | |
| $35.12 | $58.23 | $103.07 | +459% | Bullish | |
| $60.19 | $111.44 | $213.29 | +969% | Bullish | |
| $81.84 | $181.88 | $389.30 | +16.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.16 | $10.42 | $13.01 | +0.00% |
| August 2026 | $8.93 | $10.66 | $13.15 | +2.28% |
| September 2026 | $8.76 | $10.56 | $13.24 | -0.87% |
| October 2026 | $9.06 | $11.02 | $13.99 | +4.32% |
| November 2026 | $9.02 | $11.06 | $14.19 | +0.30% |
| December 2026 | $8.61 | $10.63 | $13.77 | -3.88% |
Click any year to see its month-by-month SLDB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SLDB to range from $5.16 to $13.77 through 2026. The $10.42 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The SLDB price prediction for 2027 points to an average of $15.27 (low $11.68, high $21.38) — a potential gain of +47% on today's $10.42. Buyers look set to stay in control over this stretch.
In 2028, SLDB is projected to trade between $15.47 and $31.03, averaging $21.08 — a potential gain of +102% from today's $10.42. That is up +38% on the projected 2027 average. Momentum favours further upside here.
Solid Biosciences Inc.'s 2029 outlook centres on $24.60, within a $17.43 to $37.62 range. That is up +17% on the projected 2028 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, SLDB could reach as high as $40.45, with a base case around $25.62 and support toward $17.59 — roughly +146% from $10.42. Momentum favours further upside here.
Expect SLDB to range from $19.64 to $47.79 through 2031. The $29.43 average target implies a +182% move from current prices. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The SLDB price prediction for 2032 points to an average of $33.51 (low $21.76, high $55.76) — a potential gain of +222% on today's $10.42. Momentum favours further upside here.
In 2033, SLDB is projected to trade between $25.80 and $69.37, averaging $40.76 — a potential gain of +291% from today's $10.42. That is up +22% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Solid Biosciences Inc.'s 2034 outlook centres on $54.58, within a $33.71 to $94.79 range. That is up +34% on the projected 2033 average. That marks a +424% change versus current levels. Momentum favours further upside here.
By 2035, SLDB could reach as high as $103.07, with a base case around $58.23 and support toward $35.12 — roughly +459% from $10.42. Buyers look set to stay in control over this stretch.
Expect SLDB to range from $60.19 to $213.29 through 2040. The $111.44 average target implies a +969% move from current prices. That is up +91% on the projected 2035 average. Momentum favours further upside here.
The SLDB price prediction for 2050 points to an average of $181.88 (low $81.84, high $389.30) — a potential gain of +16.5x on today's $10.42. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLDB today (≈ 95.96929 SLDB) could be worth
$17,454.47
+$16,454.47 (+1645%) by 2050 · US Dollar
Based on the average projected SLDB price of $181.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLDBwould be worth at today's price.
$1,000 invested in SLDB on Jul 10, 2025 (≈ 184.501842 SLDB) would be worth
$1,922.51
+$922.51 (+92.3%) today · 1.92× · US Dollar
Based on a SLDB entry price of $5.42 vs. today's $10.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.84 | $961.25 | -3.9% |
| 1 month ago | $6.61 | $1,576.4 | +57.6% |
| 3 months ago | $8.02 | $1,299.25 | +29.9% |
| 6 months ago | $5.24 | $1,988.55 | +98.9% |
| 1 year ago | $5.42 | $1,922.51 | +92.3% |
| All time (5.0y) ago | $46.8 | $222.65 | -77.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLDB forecast.
Our base-case forecast reaches $21.00 around 2028.
Implied market cap at $21.00: $2.07B
The multi-year forecast depicts upside across years, beginning with 2026 min $5.16, avg $10.84, max $14.42 and a 0 ROI with neutral sentiment. In 2027 the avg is $16.69 (ROI 54) and sentiment is bullish; 2028 shows avg $21.95 (ROI 102.5); 2029 avg $25.22 (ROI 132.7); 2030 avg $26.50 (ROI 144.4). The trajectory continues with 2031 avg $29.54 (ROI 172.5), 2032 avg $34.21 (ROI 215.6), 2033 avg $42.92 (ROI 295.9), 2034 avg $55.55 (ROI 412.5), and 2035 avg $59.21 (ROI 446.2).
For 2040 the avg is $112.82 (ROI 940.8) and for 2050 the avg is $179.46 (ROI 1555.6). The forecast remains bullish across the long horizon, though these figures are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $26.50 with a min of $17.80 and a max of $42.73, and a projected ROI of 144.4, with bullish sentiment.
Forecasts show a rising average price over time with bullish sentiment in 2027-2050 and a rising ROI, though 2026 is neutral; these are estimates and not guarantees.
Yes. The max forecasted price by year shows $99.01 in 2034, $107.63 in 2035, $222.57 in 2040, and $397.77 in 2050.
Current price is $10.84 and market cap is $1.07B.
The 30-day range runs from a low of $8.22 to a high of $14.29.
Solid Biosciences Inc. Community Discussion
0Share your Solid Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.